RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Laviana Pharma of China raised about $14 million in a B+ financing to develop its CDMO operations. Founded in 2005, Laviana offers outsourced process and manufacturing services for pharma companies, especially chemistry-related services. The company has three facilities in China — Beijing, Tianjin and Taizhou — plus a business office in the US. The company announced a similar $15 million funding in January 2081. The latest funding was led by V-Capital of Shanghai and included Guangdong’s CMW Asset Management.
